Atrophic changes on a Pap smear mean the cells collected from your cervix show signs of thinning and drying out, typically because of declining estrogen levels. This is not a diagnosis of disease. It is a description of what the cells look like under a microscope, and it is extremely common in postmenopausal women, breastfeeding mothers, and anyone else whose estrogen levels have dropped. The finding becomes medically important mainly because atrophic cells can look deceptively similar to precancerous ones, sometimes triggering follow-up procedures that turn out to be unnecessary.
Why Cervical Tissue Thins
The cervix and vaginal walls are lined with layers of cells that depend on estrogen to stay thick, moist, and well-organized. When estrogen drops, those cell layers shrink. The remaining cells can appear smaller, darker, and more crowded than usual. Under a microscope, a pathologist sees fewer of the large, flat, mature cells that characterize a healthy premenopausal cervix and more of the smaller, immature-looking cells that come from deeper tissue layers now exposed at the surface.
Menopause is the most common reason for this shift. The decline in estrogen that accompanies menopause triggers physiological changes across several tissues, including the vaginal lining.1PubMed. Estrogen receptor (ER) and ER-related receptor expression in normal and atrophic human vagina Research has shown that both aging itself and estrogen deficiency independently reduce the permeability and structure of cervical and vaginal tissue, meaning that even estrogen replacement does not fully reverse all the changes.2PubMed. Vaginal-cervical epithelial permeability decreases after menopause Part of the thinning responds to hormone treatment, but some of it is simply a consequence of getting older and persists regardless of estrogen levels.3PubMed. Effects of menopause and estrogen on cervical epithelial permeability
Estrogen also plays a role in maintaining the vaginal microenvironment. It drives the cells lining the vagina to store glycogen, which in turn feeds beneficial Lactobacillus bacteria that keep vaginal pH low and the environment inhospitable to harmful organisms. When estrogen signaling is disrupted, glycogen drops, Lactobacillus populations shrink, and pH rises, creating conditions that can contribute to irritation and infection alongside the tissue thinning visible on a Pap smear.4PubMed Central. Vaginal epithelial estrogen receptor α coordinates glycogen deposition, microbial stability, and pH regulation in mice
When Atrophy Shows Up Outside of Menopause
Though menopause is the most frequent cause, any condition that suppresses estrogen can produce atrophic changes on a Pap smear. Breastfeeding is a classic example. During lactation, elevated prolactin levels suppress ovarian estrogen production, and studies of postpartum women have found that atrophic smear patterns predominate in those who breastfeed, particularly between three and six weeks after delivery. Among non-breastfeeding mothers, only about a third showed an atrophic pattern during that same window.5PubMed. Hormonal patterns in vaginal smears from puerperal women These changes are temporary and resolve once breastfeeding ends and normal hormonal cycling resumes.
Other situations that can produce atrophic Pap findings include:
- Hormonal medications: Certain drugs used to treat endometriosis, fibroids, or hormone-sensitive cancers deliberately lower estrogen, which can thin cervical tissue.
- Premature ovarian insufficiency: When the ovaries stop functioning normally before age 40, the same low-estrogen tissue changes appear much earlier than expected.
- Pelvic radiation: Radiation therapy for cervical or other pelvic cancers can damage the cervical lining and produce cellular changes that overlap with atrophy, including enlarged cells, vacuolation, and loss of normal texture.6PubMed Central. Cervical cytology: Radiation and other therapy effects
Radiation-related changes deserve special mention because they can persist long after treatment ends and can complicate the interpretation of future Pap smears. If you have had pelvic radiation, make sure your clinician and the pathologist reading your Pap are aware of your history.
How Atrophic Cells Mimic Precancer
This is the part that causes the most anxiety. When cervical cells thin out and lose their normal layered architecture, they can develop features that look worryingly similar to precancerous changes under the microscope. The nuclei may appear larger relative to the cell body, the cells may cluster in ways that resemble abnormal growth, and the overall pattern can be difficult to distinguish from what pathologists call atypical squamous cells of undetermined significance (ASCUS) or even high-grade squamous intraepithelial lesion (HSIL).
Research has confirmed this is a real and measurable problem. One study examining cervical biopsy outcomes in women whose Pap smears showed higher-than-low-grade abnormalities found that smears with an atrophic cellular pattern had significantly higher false-positive rates compared to smears from women without atrophy. The atrophic cell changes led pathologists to overinterpret what they were seeing, flagging benign tissue changes as potentially precancerous.7PubMed Central. Pattern of cervical biopsy results in cases with cervical cytology interpreted as higher than low grade in the background with atrophic cellular changes Separate analysis has concluded that benign atrophy-related changes can convincingly simulate ASCUS and even changes that suggest viral infection, and that this mimicry is a recognized source of diagnostic concern not just in Pap smears but in tissue biopsies as well.8Cancer Cytopathology. Squamous atypia in the atrophic cervical vaginal smear
The practical consequence is that a postmenopausal woman with atrophic changes may receive a result suggesting she needs colposcopy or biopsy, when the underlying tissue is actually normal. False-positive cervical dysplasia results have even been described as an early sign of genitourinary syndrome of menopause, the broader condition that includes vaginal dryness, urinary symptoms, and tissue thinning caused by estrogen loss in the perimenopause and beyond.9The Journal of Sexual Medicine. False Positive Pap Smear as The First Sign of Genitourinary Syndrome of Menopause
The Estrogen-and-Repeat Strategy
When a pathologist suspects that atrophy is muddying the picture, the standard clinical approach is straightforward: prescribe a short course of topical vaginal estrogen, wait for the tissue to plump back up, then repeat the Pap smear. The idea is that estrogen therapy reverses the atrophy-related changes, and if the earlier “abnormal” result was actually just atrophy in disguise, the repeat smear should come back normal.7PubMed Central. Pattern of cervical biopsy results in cases with cervical cytology interpreted as higher than low grade in the background with atrophic cellular changes
Vaginal estrogen cream has been studied specifically for this purpose and shown to produce significant improvements. In one study of menopausal women, treatment led to measurable changes in vaginal pH, the maturation index of vaginal cells (a measure of how estrogen-responsive the tissue is), and relief from symptoms like dryness, itching, burning, and pain during intercourse.10PubMed Central. Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women A Cochrane review of multiple formulations, including creams, pessaries, tablets, and estradiol-releasing rings, found that all of these intravaginal estrogen preparations are effective for treating vaginal atrophy symptoms.11Cochrane Database of Systematic Reviews. Oestrogenic preparations for vaginal atrophy in postmenopausal women
Beyond just clearing up ambiguous Pap results, local estrogen therapy has broader benefits. A review of the evidence found that vaginally applied estrogen can improve quality of life, have favorable effects on urinary tract infections and incontinence, and support better outcomes for vaginal surgery.12PubMed Central. Local Effects of Vaginally Administered Estrogen Therapy: A Review For many women, the short course prescribed to resolve a confusing Pap result ends up addressing symptoms they had been living with but not connecting to their hormonal status.
When Estrogen Is Not an Option
Not everyone can or wants to use vaginal estrogen. Women with a history of hormone-sensitive breast cancer, for instance, are often advised to avoid estrogen-based treatments. For these women, vaginal moisturizers and lubricants are considered first-line therapy.13PubMed Central. Use of Moisturizers and Lubricants for Vulvovaginal Atrophy
Vaginal moisturizers, applied regularly rather than only before intercourse, work by adhering to the vaginal lining and slowly releasing moisture over time. Some evidence suggests they can be similarly effective to topical estrogen for symptom relief. Lubricants, on the other hand, provide temporary comfort during sexual activity but do not produce lasting changes in the tissue.14PubMed. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview Neither moisturizers nor lubricants will reverse the cellular appearance of atrophy on a Pap smear the way estrogen can, so if clarifying an ambiguous Pap result is the goal, a conversation with your clinician about whether a short estrogen course is safe in your specific situation is worth having.
The Disconnect Between Pap Language and What You Actually Feel
One of the more frustrating aspects of the phrase “atrophic vaginitis” or “atrophic changes” on a Pap report is that it implies you should be experiencing symptoms, when you may feel perfectly fine. Research examining whether a Pap smear diagnosis of atrophic vaginitis actually correlates with clinical symptoms found that it does not. The study concluded that the Pap test’s diagnosis of atrophic vaginitis does not reliably match what women experience, and recommended a shift toward terminology that does not suggest a disease process.15Menopause. Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation?
This matters because the language on a lab report can shape how worried you feel. Women who receive abnormal or unclear Pap results often find the terminology confusing and struggle to get clear explanations from their doctors. One qualitative study found that most women wanted to participate in decisions about their care but had difficulty understanding medical terms and felt unable to ask questions during consultations.16BMJ. Women’s understanding of abnormal cervical smear test results: a qualitative interview study The way results are communicated can itself have a significant psychological impact, particularly when borderline or mildly abnormal findings are involved.17PubMed. Communicating mild and borderline abnormal cervical smear results: how and what are women told?
If your report says “atrophic changes” and you are not sure what it means for you specifically, asking your clinician a direct question can help: “Does this need any follow-up, or is this just what my cells look like now?” In most cases, the answer is the latter.
Cervical Cancer Screening After 65
Atrophic changes become more relevant in the context of a broader debate about when to stop cervical cancer screening. Current guidelines generally recommend that women can stop getting Pap smears after age 65 if they have had adequate prior screening, defined as three consecutive negative Pap results or two consecutive negative co-test results within the prior ten years, with the most recent test done within the last five years. Screening should continue for at least twenty years after management of a precancerous lesion, even if that extends past 65.18U.S. Preventive Services Task Force. Cervical Cancer: Screening
But this cutoff is not without controversy. Roughly one in five new cervical cancer cases occurs in women over 65, raising questions about whether the current stopping point leaves a meaningful gap.19PubMed Central. It’s time to re-evaluate cervical Cancer screening after age 65 The irony is that the very age group most likely to show atrophic changes on screening, and therefore most likely to receive ambiguous or false-positive results, is also the group where real cancers still occur. A study from the Heart and Estrogen/Progestin Replacement Study found that the positive predictive value of cervical smears was poor in previously screened postmenopausal women, meaning that when their Paps flagged something, it was usually nothing.20PubMed. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS) That creates a tricky situation: screening catches very little real disease in this population but generates a steady stream of false alarms that lead to unnecessary procedures.
If you are over 65 and still being screened, the atrophy factor is worth discussing with your provider. Understanding that atrophic changes can produce misleading results may help you and your clinician decide together whether a mildly abnormal result warrants aggressive follow-up or a calmer wait-and-retest approach.
Why Colposcopy Gets Harder After Menopause
When a Pap smear result does warrant closer investigation, the next step is usually colposcopy, a procedure where a clinician uses a magnifying instrument to examine the cervix directly and may take small tissue samples. In premenopausal women, the key anatomical landmark, the squamocolumnar junction where the two types of cervical cells meet, is usually visible on the outer surface of the cervix. This is the area most vulnerable to precancerous changes, and seeing it clearly is essential for an adequate exam.
In postmenopausal women, atrophy changes the anatomy. The squamocolumnar junction often retreats up into the cervical canal where it cannot be seen, and the cervical opening itself may narrow (a condition called stenosis). These changes can make the colposcopy exam inadequate, meaning the clinician cannot fully evaluate the area of concern.21PubMed Central. Colposcopy PostMenopause: A Challenge in Cervical Cancer Elimination Goal! This is another reason why a short course of vaginal estrogen before colposcopy is sometimes recommended: it can help the tissue regain enough fullness and flexibility for the junction to become visible again, making the exam more reliable and potentially less uncomfortable.
The combination of higher false-positive Pap rates and less reliable colposcopy in postmenopausal women means that the diagnostic pathway after an abnormal result is genuinely harder in this population. It is a recognized clinical challenge, and the fact that it exists is worth knowing if you are navigating one of these follow-ups. Being aware that atrophy complicates both the screening test and the follow-up exam can help you have a more informed conversation about whether the pace and intensity of your workup matches the actual level of risk.